I have averged in to this over a few months...Love the divy and no insiders are buying..
Machines hard to beat them
so true they pay him big buck hedge funds for his stupid opinions before they are written and published.
Total Cash (mrq): 290.12M
Total Cash Per Share (mrq): 13.58
Total Debt (mrq): 0.00
made 8 points on QLYS and up 5 on BBSI same type of attacks.
this company has no debt a 12+ a share in cash
Avalanche noted that the study wasn't designed to show statistically significant differences between the active and control subjects.
No serious adverse events from the treatment were observed in the study, the company said.
The Menlo Park, Calif., clinical-stage biotechnology company, which went public last year, intends to start another mid-stage study of its lead drug this year.
Regeneron Pharmaceuticals Inc. (REGN) has a right of first refusal on Avalanche's lead drug.
my opinion only ....
This should have a very nice bounce Regeneraon a partner